Phase 2 Leukaemia Trial, Recruiting NCT06984536 Sponsor: Peking University People's Hospital Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06984536
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with acute leukemia in complete remission (meaning no signs of disease are currently detectable) and/or a bone marrow disorder called myelodysplastic syndrome, who are having their first bone marrow/stem cell transplant from a donor
  • People aged 12 to 65 years (any gender)
  • People whose planned transplant uses a half-matched donor (such as a parent or child), but not a donor who is the patient's mother or a donor from the same generation such as a sibling (confirm with trial site)
  • People whose general physical functioning is rated at 3 or below on a standard medical scale, meaning they are able to carry out some self-care even if limited (confirm with trial site)
  • People whose heart is pumping blood effectively, with a measurement called ejection fraction above 55%
  • People whose kidney function blood test result is within an acceptable range (no more than 1.5 times the upper limit of normal for creatinine)

Who may not be able to join:

  • People with serious problems affecting the brain, heart, kidneys, or liver
  • People whose cancer or blood disorder has not responded to previous treatments (refractory disease)
  • People who have another cancer that currently requires treatment
  • People with a severe active infection that is not under control
  • People whose doctors estimate they have less than 3 months to live
  • People with a history of severe allergic reactions
  • People who are pregnant or breastfeeding
  • People whom the trial doctor considers unsuitable for the study for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-010-8832-6000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Peking University People's Hospital
Registry
ClinicalTrials.gov
Start date
21 May 2025
Est. completion
31 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Non-relapse mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov